Clinical trials for R-GemOx

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44349 clinical trials with a EudraCT protocol, of which 7376 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

16 result(s) found for: R-GemOx. Displaying page 1 of 1.

EudraCT Number: 2005-002344-26	Sponsor Protocol Number: R-GEMOX	Start Date*: 2005-07-07
Sponsor Name:GELA
Full Title: GEMCITABINE-OXALIPLATINE PLUS RITUXIMAB (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NON ELIGIBLE FOR HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOTRANSPLAN...
Medical condition: Refractory/relapsed patients with CD 20 positive large B-cell lymphoma
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: BE (Completed)
Trial results: View results

EudraCT Number: 2018-003727-10

Sponsor Protocol Number: MO40598

Start Date*: 2019-12-16

Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd

Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-G...

Medical condition: Relapsed/refractory diffuse large B-cell lymphoma (DLBL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004864	10012857	Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory	LLT
	21.1	100000004864	10012856	Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent	LLT
	21.0	100000004864	10012855	Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Completed) FI (Completed) SE (Completed) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2011-003849-18

Sponsor Protocol Number: CMC-R-GEMOX

Start Date*: 2012-06-07

Sponsor Name:LYSARC

Full Title: A MULTI-CENTER, PHASE IB/II, OPEN LABEL, SINGLE ARM STUDY OF INOTUZUMAB OZOGAMICIN PLUS RITUXIMAB (R-CMC544) ALTERNATING WITH GEMCITABINE-OXALIPLATIN PLUS RITUXIMAB (R-GEMOX) IN PATIENTS AGED FROM ...

Medical condition: CD20 and CD22 positive diffuse large B-cell lymphoma in first or second relapse or refractory to first and/or second line treatment

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012822	Diffuse large B-cell lymphoma refractory	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed)

Trial results: View results

EudraCT Number: 2016-003408-29

Sponsor Protocol Number: 5F9003

Start Date*: 2019-11-04

Sponsor Name:Gilead Sciences, Inc.

Full Title: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma

Medical condition: Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma.

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012821	Diffuse large B-cell lymphoma recurrent	PT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029624	Non-Hodgkin's lymphoma unspecified histology indolent stage III	PT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029601	Non-Hodgkin's lymphoma refractory	PT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029600	Non-Hodgkin's lymphoma recurrent	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012822	Diffuse large B-cell lymphoma refractory	PT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029623	Non-Hodgkin's lymphoma unspecified histology indolent stage II	PT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029622	Non-Hodgkin's lymphoma unspecified histology indolent stage I	PT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065856	Non-Hodgkin's lymphoma unspecified histology indolent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2016-002272-27

Sponsor Protocol Number: DSHNHL2015-1

Start Date*: 2017-04-06

Sponsor Name:Saarland University

Full Title: Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabin...

Medical condition: Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	22.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029547	Non-Hodgkin's lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) FR (Completed) BE (Completed) NL (Ongoing) PL (Completed) AT (Completed) PT (Completed)

Trial results: (No results available)

EudraCT Number: 2021-003313-18

Sponsor Protocol Number: MK-2140-003

Start Date*: 2022-01-10

Sponsor Name:Merck Sharp & Dohme LLC

Full Title: A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Larg...

Medical condition: Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10012857	Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2006-001985-17

Sponsor Protocol Number: H6Q-MC-S013

Start Date*: 2006-10-25

Sponsor Name:Eli Lilly and Company limited

Full Title: An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine, and Oxaliplatin plus Oral Enzastaurin as Treatment for Patients with Relapsed Diffuse Large B-Cell Lymphoma

Medical condition: high-risk diffuse large B-cell lymphoma (DLBCL )

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10012822	Diffuse large B-cell lymphoma refractory	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2016-002654-21

Sponsor Protocol Number: RHMCAN1219

Start Date*: 2017-11-23

Sponsor Name:University Hospital Southampton NHS Foundation Trust

Full Title: A PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY.

Medical condition: Diffuse large B-cell lymphoma (most common type of non-Hodgkins lymphoma)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012818	Diffuse large B-cell lymphoma	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: View results

EudraCT Number: 2014-004794-16

Sponsor Protocol Number: 1270.11

Start Date*: 2015-10-21

Sponsor Name:SCS Boehringer Ingelheim Comm. V

Full Title: An open label multicenter Phase Ib/II trial to determine the dose of BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) and the efficacy of BI 836826 – GemOx versus rituximab ( R ) w...

Medical condition: Patients with relapsed/refractory diffuse large B-cell lymphoma including transformed follicular lymphoma) who have been previously treated with an anti-CD20 monoclonal antibody (e.g. rituximab) in...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012822	Diffuse large B-cell lymphoma refractory	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2008-007305-36

Sponsor Protocol Number: GEL-TAMO/R-GemOx-08-04/v2

Start Date*: 2009-05-25

Sponsor Name:GELTAMO (Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea)

Full Title: Estudio fase II prospectivo, abierto, multicéntrico de Gemcitabina, Oxaliplatino y Dexametasona + Rituximab en pacientes con linfomas agresivos (difuso de céluls grandes B y del manto) en recaída o...

Medical condition: Linfoma difuso de células grandes B y Linfoma del manto

Disease:	Version	SOC Term	Classification Code	Term	Level
	9		10012821	Diffuse large B-cell lymphoma recurrent	LLT
	9		10026800	Mantle cell lymphoma recurrent	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed)

Trial results: (No results available)

EudraCT Number: 2020-001021-31

Sponsor Protocol Number: GO41944

Start Date*: 2021-01-22

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN VERSUS RITUXIMAB IN COMBINATION WITH GEMCITA...

Medical condition: Relapsed or refractory diffuse large B-cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-003016-27

Sponsor Protocol Number: GCT3013-05

Start Date*: 2021-04-06

Sponsor Name:Genmab A/S

Full Title: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Medical condition: B-cell Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004851	10012819	Diffuse large B-cell lymphomas	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-003908-14

Sponsor Protocol Number: M-2020-371

Start Date*: 2021-07-07

Sponsor Name:Miltenyi Biomedicine GmbH

Full Title: A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diff...

Medical condition: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10003903	B-cell lymphoma refractory	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10003902	B-cell lymphoma recurrent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2015-005837-37

Sponsor Protocol Number: 15-201

Start Date*: 2016-03-15

Sponsor Name:CHU CAEN

Full Title: ASSOCIATION RITUXIMAB - BENDAMUSTINE - ARACYTINE DANS LE TRAITEMENT DES LYMPHOMES B DIFFUS À GRANDES CELLULES REFRACTAIRES OU EN RECHUTE : ETUDE DE PHASE II

Medical condition: Patients atteints de lymphome B diffus à grandes cellules en rechute ou réfractaires

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004864	10012855	Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2019-002499-14	Sponsor Protocol Number: PI2018_843_0051	Start Date*: 2021-05-26
Sponsor Name:CHU Amiens-Picardie
Full Title: RELYAGE (Relapse LYmphoma AGEd) : Assessment of survival and autonomy with Rituximab-Lenalidomide and Rituximab-Chemotherapy for elderly patients with relapsed diffuse large-B cell lymphoma : a ran...
Medical condition: diffuse large B cell lymphoma
Disease:
Population Age: Elderly		Gender: Male, Female
Trial protocol: FR (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2015-005390-21

Sponsor Protocol Number: IBDCL-GELTAMO-2015

Start Date*: 2016-02-19

Sponsor Name:GELTAMO

Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in patients w...

Medical condition: diffuse large B-cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.1	100000004851	10012819	Diffuse large B-cell lymphomas	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Wed Jul 16 19:04:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA